Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (March 2021)
17 slides from Nyrada's investor presentation, Mar 18, 2021
Slide 1: Investor Presentation
For personal use only INVESTOR PRESENTATION James Bonnar, Nyrada CEO March 2021 Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board. 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 3: Nyrada Inc: Vision and Mission
Nyrada Inc For personal use only Vision We can improve lives and offer hope through innovation Deliver a cost-competitive and convenient cholesterol-lowering treatment to help achieve target safe cholesterol level Reduce risk of cardiovascular disease (heart attack and stroke) Deliver the first-ever
Slide 4: Business Strategy
Business Strategy For personal use only Drug discovery Cholesterol-Lowering drug and early-stage Oral PCSK9 inhibitor to be used alone as a developer monotherapy, or in combination with a statin - Out-license following Phase I study Brain Injury drug Intravenous and intranasal drug to help people wh
Slide 5: Problem – High LDL Cholesterol
Problem – High LDL Cholesterol For personal use only High LDL Cholesterol leading cause of cardiovascular disease Cardiovascular disease responsible for 1-in-4 deaths1 62.6 million US adults with elevated LDL-C2 1. Centers for Disease Control and Prevention, Heart Disease Facts: Virani SS, Alonso A,
Slide 6: Statin Drugs
Statin Drugs For personal use only 19.4 million 27.4 million Unable to achieve US adults with elevated LDL-C target despite LDL-C are taking a statin taking statin therapy Low cost Suboptimal efficacy Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin e
Slide 7: Current PCSK9 Inhibitors
Current PCSK9 Inhibitors For personal use only Binds to PCSK9 protein Effective, combined with a statin Blocks action of PCSK9 on cholesterol receptor Expensive US$5,800 per year Inconvenient (2-4 weekly injections) Statin + current PCSK9 inhibitor = expensive and inconvenient 7
Slide 8: Nyrada's Unique Solution
Nyrada’s Unique Solution For personal use only Oral PCSK9 Convenient Cost- treatment for patient effective Small molecule PCSK9 inhibitor overcomes longstanding challenge of oral treatment Can be combined with statin to deliver a first ever single pill PCSK9/statin treatment 8
Slide 9: Cholesterol Reduction with NYX-PCSK9i
Cholesterol Reduction with NYX-PCSK9i For personal use only 9
Slide 10: Brain Injury Problem
Brain Injury Problem For personal use only - Annually in the US, 2.8 Neurology / physical million people sustain a rehabilitation are the only - High mortality traumatic brain injury (TBI) - Severe life-long disability existing therapies - 800,000 suffer a stroke - One drug class for stroke - High o
Slide 11: Market Opportunity
Market Opportunity For personal use only In the US, UK, Europe and Japan alone, the size of the TBI market in 2020 was US$ 6,739 million1 Estimated to grow at a CAGR of 5.54% between 2018–20301 In the US, total TBI related emergency department visits, hospitalisations and deaths (EDHDs) increased by
Slide 12: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 13: Walter Reed & UNSW Collaboration
Walter Reed & UNSW Collaboration For personal use only • Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research and UNSW Sydney • Efficacy and mechanism of action studies to be conducted on Nyrada’s preclinical neuroprotection compound • Aligns with W
Slide 14: Program Status & Recent Achievements
Program Status & Recent Achievements For personal use only First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering Drug: late-CY 2021 - Brain Injury Drug: mid-CY 2022 Results from an in vivo cholesterol efficacy study showed a 57% reductio
Slide 15: Board of Directors
Board of Directors For personal use only Mr Marcus Dr Rüdiger Mr John Moore Dr Ian Dixon Christopher Cox Mr Peter Marks Frampton Weseloh Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director 15
Slide 16: Key Metrics & News Flow
Key Metrics & News Flow For personal use only Market capitalisation CY 2021 CY 2022 $35M (as at 17 March 2021) Share price Cholesterol-lowering program $0.315 to enter clinic: (as at 17 March 2021) Brain injury program CDIs free float 77,719,770 to enter clinic: CDIs 24 months escrow 33,105,853 Cash
Slide 17: Discover More & Follow Us
Discover More & Follow Us For personal use only info@nyrada.com www.nyrada.com @nyrada_inc @nyrada_inc Brain Injury Solution Animation Cholesterol-Lowering Animation ASX: NYR 17